Amidst dwindling share prices and widespread criticism, Pfizer CEO Albert Bourla appears to have withstood an attempted ousting by activist investor Starboard Value. On 6 October, Bourla received ...

As one of the largest vaccine makers, Pfizer has a big part of its business hinging on potential immunization policy changes under the incoming Trump administration. So when vaccine skeptic Robert F.

Pfizer (NYSE:PFE) just dropped some solid news for investors: 2025 revenue projections are right where Wall Street expected, between $61 billion and $64 billion, with adjusted earnings per share ...

Pfizer CEO met RFK Jr. and Trump, developed good relationship Trump committed to reforming pharmacy benefit managers, reducing medicine costs Pfizer faces investor pressure over strategy, shares ...

Beata Zawrzel / NurPhoto via Getty Images Pfizer on Tuesday affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.

Goldman Sachs projects Pfizer’s 2025 EPS at $3.13, beating consensus of $2.89. Paxlovid sales expected to reach $4.3 billion vs. consensus of $3.7 billion; Vyndaqel forecast misses. Pfizer Inc ...

Pfizer forecast 2025 revenue and earnings in line with market expectations, despite a $1 billion hit from the redesign of federal drug benefits. The New York pharmaceutical giant Tuesday said it ...

Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent ...

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of investors, aiming to add eight ...

Locking horns with activist investor Starboard Value, Pfizer CEO Albert Bourla’s position seems increasingly secure. Credit: Ryan Muir/ Getty Images Amidst dwindling share prices and widespread ...

BOULDER — Ambrosia Biosciences Inc., a recently formed drug-discovery company, has moved into Pfizer Inc.’s (NYSE: PFE) previously shuttered Boulder research and development facilities and closed a ...